Clinical analysis of Novomix 30 combined with Galvus in the treatment of newly diagnosed type 2 diabetes

Objective To explore the clinical efficacy of Novomix 30 combined with Galvus in the treatment of newly diagnosed type 2 diabetes. Methods 102 cases with newly diagnosed type 2 diabetes in our hospital from October 2011 to October 2012 were selected and divided into two groups,the observation group had 51 cases,the control group had 51 cases. The patients in the observation group were treated by Novomix30, the patients in the control group were treated by Novomix30 combined with Galvus,compared and analyzed the clinical efficacy of the two groups. Results After the treatment,in the observation group,the fasting plasma glucose was (7.21±2.21)mmol/L,the postprandial blood glucose value was (9.34±3.01)mmol/L;in the control group,the fasting plasma glucose was(10.23±3.02)mmol/L,the postprandial blood glucose value was (14.87±3.23)mmol/L. After the treatment,the fasting plasma glucose and postprandial blood glucose value of the two groups had significant difference(P0.05). Conclusion Novomix 30 combined with Galvus in the treatment of newly diagnosed type 2 diabetes has precise clinical efficacy,it's worthy of promotion.